Proteostasis Response to Protein Misfolding in Controlled Hypertension

Cells. 2022 May 19;11(10):1686. doi: 10.3390/cells11101686.

Abstract

Hypertension is the most determinant risk factor for cardiovascular diseases. Early intervention and future therapies targeting hypertension mechanisms may improve the quality of life and clinical outcomes. Hypertension has a complex multifactorial aetiology and was recently associated with protein homeostasis (proteostasis). This work aimed to characterize proteostasis in easy-to-access plasma samples from 40 individuals, 20 with controlled hypertension and 20 age- and gender-matched normotensive individuals. Proteostasis was evaluated by quantifying the levels of protein aggregates through different techniques, including fluorescent probes, slot blot immunoassays and Fourier-transform infrared spectroscopy (FTIR). No significant between-group differences were observed in the absolute levels of various protein aggregates (Proteostat or Thioflavin T-stained aggregates; prefibrillar oligomers and fibrils) or total levels of proteostasis-related proteins (Ubiquitin and Clusterin). However, significant positive associations between Endothelin 1 and protein aggregation or proteostasis biomarkers (such as fibrils and ubiquitin) were only observed in the hypertension group. The same is true for the association between the proteins involved in quality control and protein aggregates. These results suggest that proteostasis mechanisms are actively engaged in hypertension as a coping mechanism to counteract its pathological effects in proteome stability, even when individuals are chronically medicated and presenting controlled blood pressure levels.

Keywords: body fluids; clusterin; endothelin 1; fibrils; hypertension; oligomers; protein aggregation; proteostasis; ubiquitin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Hypertension*
  • Protein Aggregates
  • Proteome
  • Proteostasis* / physiology
  • Quality of Life
  • Ubiquitin

Substances

  • Protein Aggregates
  • Proteome
  • Ubiquitin

Grants and funding

This work was supported by the Portuguese Foundation for Science and Technology (FCT) Centro2020/Portugal2020 and FEDER/Compete2020 funds via the Institute for Biomedicine iBiMED (UID/BIM/04501/2019) and the Ph.D fellowships to M.G. (SFRH/BD/128893/2017), S.M. (SFRH/BD/131820/2017) and M.T. (2020.08565.BD), and via the MEDISIS (CENTRO-01-0246-FEDER-000018) and pAGE (CENTRO-01-0145-FEDER-000003) programs that included the post-doc fellowship of D.T. (BPD/UI98/7844/2017) and R.E.B. (BPD/UID/BIM/771/2018).